Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2021-05-26 Director's Dealing
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
FORM 4/A SUBMISSION
Director's Dealing
2021-05-26 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-20 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 20, 2021, reporting the company's financial results for the quarter ended March 31, 2021. It specifically states that it includes a press release announcing financial results. The document is relatively short (4090 characters) and primarily serves as a current report to announce the earnings release rather than containing detailed financial statements or comprehensive analysis. The text explicitly mentions that the press release is furnished as an exhibit and that the information is "furnished" and not "filed," indicating it is an announcement rather than the full earnings report itself. Therefore, this document fits the definition of an Earnings Release (ER) as it is the initial announcement of quarterly financial results with key highlights only, not a full interim or annual report.
2021-05-20 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the departure of a senior officer, Wendy Johnson, the Chief Development Officer, including her retirement plans and the company's search for a replacement. This fits the category of announcements related to changes in the company's board of directors or senior management. The document length is 3070 characters, which is relatively short and focused on a management change event. Therefore, the appropriate classification is 'Board/Management Information' (MANG).
2021-05-14 English
NEW ENTERPRISE ASSOCIATES 15, L.P. / RENEO PHARMACEUTICALS, INC. -- SCHEDULE 13D
Major Shareholding Notification
2021-04-23 English
SC 13D
Major Shareholding Notification
2021-04-20 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.